Pharmacodynamics and biodistribution of [195mPt]cisplatin(CISSPECT®) in head and neck squamous cell carcinoma.

"Declarations Ethics approval and consent to participateAll animal experiments were performed according to the ARRIVE guidelines, Dutch and EU legislations, and the protocol was approved by the Institutional Review Board (Vrije Universisteit Amsterdam) on animal experimentation. Consent for publicationNot applicable. Competing interestsThe authors declare that K. van der Schilden is employee of the Nuclear Research & Consultancy Group (NRG), which may be considered as potential competing interest. All other authors have no relevant financial or non-financial interests to disclose. Competing interests The authors declare that K. van der Schilden is employee of the Nuclear Research & Consultancy Group (NRG), which may be considered as potential competing interest. All other authors have no relevant financial or non-financial interests to disclose."

"Funding This work was supported by the Design Project (KWF-A6C7072)."